Clinical evidence for the EU market refers to scientific proof of a health technology product’s safety and efficacy in accordance with the MDR regulation. Requirements vary by device risk class and may include clinical investigations, literature reviews, or the use of existing real-world data. To obtain and maintain CE marking, manufacturers must demonstrate a sufficient level of clinical evidence — for example, to ensure patient safety.
What clinical evidence does the EU MDR regulation require from health technology?
The EU MDR regulation requires adequate clinical evidence from all medical devices according to their risk class. Clinical evidence means scientific proof demonstrating a device’s clinical benefits, safety, efficacy, and performance under real-world conditions of use.
The required level of clinical evidence varies depending on risk class and intended purpose. Generally, innovative devices or those offering new treatment modalities require their own clinical device investigation. For Class I devices, a sufficient level may potentially rely on other studies and the device’s technical safety.
Documentation requirements include a clinical evaluation plan and report, analyzing all available clinical data. The report must demonstrate the acceptability of the benefit–risk ratio, and also show how the device’s clinical benefits, safety, efficacy, and performance will be monitored throughout its time on the market or over its lifecycle.
When is existing clinical data sufficient for EU market access?
Existing clinical data is sufficient when a scientifically justified equivalence to a device already on the market can be demonstrated. This requires showing technical, biological, and clinical equivalence through a detailed comparison — technical similarity alone is not enough.
Equivalence assessment principles require that the reference device has an adequate clinical history on the EU market and represents the same technological generation. The acceptability of literature reviews depends on their scope and systematic nature — marketing material alone is not sufficient as evidence.
Clinical evidence requirements for the EU market are multifaceted and depend strongly on the characteristics of the device. Choosing the right strategy saves significant time and resources in the market access process. Health technology regulation is continuously evolving, which is why expert guidance is essential to ensure successful product development.
